Agentic AI in Healthcare Market OverviewThe global agentic AI in healthcare market is expected to grow at a rate of 35-40% ...

GenomOncology, a precision medicine software company, and Pillar Biosciences, a leader in Decision Medicine™, today announced ...

By addressing inefficiencies before they occur and ensuring that every recommendation is backed by evidence-based research, IllumiCare is redefining how hospitals approach clinical waste.

Providers unknowingly prescribe expensive medications when equally effective and more affordable alternatives are available, order repetitive lab tests, and conduct duplicate imaging studies—all forms ...

The interventions have helped MultiCare achieve a 26% acceptance rate for recommendations, with 23% for medications and 36% for lab orders. These numbers may sound low, but they far exceed national ...

In the deal, GenomOncology will integrate Pillar's RUO NGS panels into its clinical decision support platform to enable personalized cancer treatment insights.

Daniel Rubin, PharmD, BCOP, discussed a study showing how a clinical decision support tool can improve the documentation of ...

The effectiveness of AI-powered CDSSs in clinical practice hinges on clinicians' trust and their willingness to rely on AI ...

Black Book Research's rankings are exclusively determined by comprehensive user and client experience surveys. Notably, the organization does not solicit or accept any fees for vendor inclusion or lis ...